Cancer biotherapy & radiopharmaceuticals最新文献

筛选
英文 中文
An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (177Lu)-DOTATATE. Lutetium 177 (177Lu)-DOTATATE治疗神经内分泌肿瘤的剂量分析
IF 3.4
Cancer biotherapy & radiopharmaceuticals Pub Date : 2022-02-01 Epub Date: 2021-06-16 DOI: 10.1089/cbr.2021.0071
Bilal Kovan, Zeynep Gözde Özkan, Bayram Demir, Duygu Tunçman, Emine Göknur Işik, Duygu Has Şimşek, Fikret Büyükkaya, Cüneyt Türkmen, Yasemin Şanli
{"title":"An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (<sup>177</sup>Lu)-DOTATATE.","authors":"Bilal Kovan,&nbsp;Zeynep Gözde Özkan,&nbsp;Bayram Demir,&nbsp;Duygu Tunçman,&nbsp;Emine Göknur Işik,&nbsp;Duygu Has Şimşek,&nbsp;Fikret Büyükkaya,&nbsp;Cüneyt Türkmen,&nbsp;Yasemin Şanli","doi":"10.1089/cbr.2021.0071","DOIUrl":"https://doi.org/10.1089/cbr.2021.0071","url":null,"abstract":"<p><p><b><i>Background:</i></b> The aim of this study is to clarify the critical organs that limit treatment scheme and also evaluate the validity of currently used critical organ threshold values in neuroendocrine tumor (NET) patients, receiving peptide receptor radionuclide therapy (PRRT) with Lutetium 177 (<sup>177</sup>Lu)-DOTATATE. <b><i>Materials and Methods:</i></b> Thirty-six NET patients (ages 16-73 years) who received <sup>177</sup>Lu-DOTATATE treatment were evaluated retrospectively in this study. Dosimetric calculations were made using medical internal radionuclide dose method. For calculation of organ doses, Internal Dose Assessment at Organ Level/Exponential Modelling 1.1 software program was used. Follow-up data were used to determine the organ failure. <b><i>Results:</i></b> A total of 141 cycles and mean of 3.91 (±1.33) cycles were applied to the patients. A mean of 691 mCi (±257 mCi) <sup>177</sup>Lu-DOTATATE infusion in total and a dose between 70 and 200 mCi per treatment was applied to patients. Seven of 36 patients reached 23 Gy renal dose limit. In these patients, although kidney doses were between 23 and 29 Gy, there was no diminution in renal functions during follow-up. Two of 36 patients reached total bone marrow dose of 2 Gy limit. Bone marrow suppression did not develop in these patients. <b><i>Conclusion:</i></b> The critical organs that seem to affect the treatment scheme in PRRT with <sup>177</sup>Lu-DOTATATE are kidney and bone marrow. Although there are established threshold levels, derived from radiotherapy experience, more studies are needed to clarify these dose limits in systemic radionuclide therapies such as PRRT.</p>","PeriodicalId":518937,"journal":{"name":"Cancer biotherapy & radiopharmaceuticals","volume":" ","pages":"17-22"},"PeriodicalIF":3.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39237293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin. 受体-操作者特征和预处理EBV-DNA病毒载量对接受调强放疗同时顺铂治疗的II期鼻咽癌患者ERCC1 mRNA水平的预测价值
IF 3.4
Cancer biotherapy & radiopharmaceuticals Pub Date : 2022-02-01 Epub Date: 2021-03-24 DOI: 10.1089/cbr.2020.4474
Li Hua, Shaojun Chen, Mengzhuan Wei, Yongqi Shen, Jianxin Long, Zhan Lin, Yiliang Meng, Chengxian Guo, Haixin Huang, Xiaoning Tu, Min Yao
{"title":"Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.","authors":"Li Hua,&nbsp;Shaojun Chen,&nbsp;Mengzhuan Wei,&nbsp;Yongqi Shen,&nbsp;Jianxin Long,&nbsp;Zhan Lin,&nbsp;Yiliang Meng,&nbsp;Chengxian Guo,&nbsp;Haixin Huang,&nbsp;Xiaoning Tu,&nbsp;Min Yao","doi":"10.1089/cbr.2020.4474","DOIUrl":"https://doi.org/10.1089/cbr.2020.4474","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; The molecular mechanisms underlying chemoresistance are still poorly understood in nasopharyngeal cancer. The protein expression of ERCC1 in DNA repair genes has been reported related to resistance platinum and predicting treatment outcomes in various malignant carcinomas, but the benefit for predicting outcomes with optimal cutoff value of ERCC1mRNA is controversial. The level of plasma Epstein-Barr virus (EBV) DNA is positively correlated with clinical stages of nasopharyngeal carcinoma (NPC). The predictive value of ERCC1mRNA from receiver-operator characteristic (ROC) and EBV-DNA level for stratified treatment with stage II NPC is exactly unclear. This study aims to assess the predictive value of combined EBV-DNA and ERCC1 in stage II nasopharyngeal cancer (NPC) patients treated with intensity-modulated radiotherapy (IMRT) with concurrent cisplatin, and provide guidance for future stratified treatment. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; A total of 86 stage II NPC patients who received IMRT and concurrent cisplatin-based chemotherapy with or without cisplatin-based adjuvant chemotherapy had measurements of ERCC1 mRNA, and pretreatment EBV-DNA levels were analyzed by real-time PCR (RT-PCR). Associations of ERCC1 mRNA and pretreatment EBV-DNA levels with clinical characteristics and survivals were evaluated. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Cutoff value of ERCC1 mRNA obtained from ROC curve was used, and there were significant differences in progression-free survival (PFS) and overall survival (OS) and overall response rate (ORR) between high expression group and low expression group (&lt;i&gt;p&lt;/i&gt; = 0.021 and 0.030 and 0.000, respectively). Patients with pretreatment EBV-DNA &lt;2000 copies/mL had significantly better PFS and ORR (&lt;i&gt;p&lt;/i&gt; = 0.024 and 0.043, respectively) and a marginally significant impact on OS (&lt;i&gt;p&lt;/i&gt; = 0.062) than those with pretreatment EBV-DNA ≥2000 copies/mL. Patients were divided into three groups by combination of ERCC1 mRNA and EBV-DNA level: ERCC1 mRNA low expression/pre-EBV-DNA &lt;2000 copies/mL, ERCC1 mRNA low expression/pre-EBV-DNA ≥2000 copies/mL, and ERCC1 mRNA high expression/pre-EBV-DNA ≥2000 copies/mL. There were significant differences in ORR among the three groups (&lt;i&gt;p&lt;/i&gt; = 0.005). The median follow-up was 62 months (range 22-84) with a follow-up rate of 90.70%. In these groups by combination of ERCC1 mRNA and EBV-DNA level, 1, 3, 5-year OS were 100%, 100%, 100%; 100%, 94.1%, 90.9%; and 100%, 85%, 72.9%, respectively (&lt;i&gt;p&lt;/i&gt; = 0.038); 1, 3, 5-year PFS were 100%, 100%, 100%; 97.1%, 91.2%, 84.8%; and 95%, 85%, 71.4%, respectively (&lt;i&gt;p&lt;/i&gt; = 0.028). Multivariate analysis showed that combination of ERCC1 mRNA and EBV-DNA levels remained independent prognostic factor but not ERCC1 mRNA and EBV-DNA alone. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; Combined ERCC1 mRNA and pre-EBV-DNA is a better prognostic biomarker in stage II NPC patients treated with concurrent chemoradiation. Patients with ERCC1 mRNA high expression/pr","PeriodicalId":518937,"journal":{"name":"Cancer biotherapy & radiopharmaceuticals","volume":" ","pages":"2-10"},"PeriodicalIF":3.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25525211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in Rats. 大鼠α粒子释放铋的全身生理药代动力学模型。
IF 3.4
Cancer biotherapy & radiopharmaceuticals Pub Date : 2022-02-01 Epub Date: 2021-06-29 DOI: 10.1089/cbr.2021.0028
Nouran R R Zaid, Peter Kletting, Gordon Winter, Ambros J Beer, Gerhard Glatting
{"title":"A Whole-Body Physiologically Based Pharmacokinetic Model for Alpha Particle Emitting Bismuth in Rats.","authors":"Nouran R R Zaid,&nbsp;Peter Kletting,&nbsp;Gordon Winter,&nbsp;Ambros J Beer,&nbsp;Gerhard Glatting","doi":"10.1089/cbr.2021.0028","DOIUrl":"https://doi.org/10.1089/cbr.2021.0028","url":null,"abstract":"<p><p><b><i>Background:</i></b> α particle emitting bismuth (<sup>212</sup>Bi) as decay product of <sup>212</sup>Pb-labeled pharmaceuticals has been effective in targeted α particle therapy (TAT). Estimating the contribution of <sup>212</sup>Bi released from its chelator to the absorbed doses in nontarget tissues is challenging in TAT. Physiologically based pharmacokinetic (PBPK) modeling can help overcome this limitation. Therefore, a whole-body <sup>212</sup>Bi-PBPK model was developed to describe the pharmacokinetics (PKs) of <sup>212</sup>Bi in rats. <b><i>Materials and Methods:</i></b> The rat <sup>212</sup>Bi-PBPK model was implemented using the modeling software SAAM II with data and parameter values from the literature. Besides other mechanisms, <sup>212</sup>Bi interactions with red blood cells, high molecular weight plasma protein, and intracellular biological thiols are described. Important PK parameters were fitted to time-activity data. Absorbed dose coefficients (ADCs) were calculated for injecting 0.774 fmol of <sup>212</sup>Bi. <b><i>Results:</i></b> <sup>212</sup>Bi uptake rates of liver, bone, small intestine, bone marrow, skin, and muscle were (0.86 ± 0.13), (3.85 ± 0.63), (0.27 ± 0.05), (1.44 ± 0.29), (0.04 ± 0.01), and (0.007 ± 0.007) per min with corresponding ADCs of 0.09, 0.03, 0.03, 0.07, 0.01, and 0.003 mGy/kBq, respectively. An ADC of 0.70 mGy/kBq was determined for kidneys. <b><i>Conclusions:</i></b> Kidneys are the dose-limiting organs in <sup>212</sup>Bi-based TAT. The <sup>212</sup>Bi-PBPK model is an effective tool to investigate the <sup>212</sup>Bi biodistribution in murine models. Integrating the <sup>212</sup>Bi-PBPK model into other murine and human PBPK models of α particle generators can help study the efficacy and safety of TAT.</p>","PeriodicalId":518937,"journal":{"name":"Cancer biotherapy & radiopharmaceuticals","volume":" ","pages":"41-46"},"PeriodicalIF":3.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39139754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Preparation of Rhenium-188-Lipiodol Using Freeze-Dried Kits for Transarterial Radioembolization: An Overview and Experience in a Hospital Radiopharmacy. 经动脉放射栓塞用冻干试剂盒制备铼-188-脂醇:某医院放射药学的综述与经验。
IF 3.4
Cancer biotherapy & radiopharmaceuticals Pub Date : 2022-02-01 Epub Date: 2021-06-08 DOI: 10.1089/cbr.2021.0043
Edathurutykalarickal Ramakurup Radhakrishnan, Viju Chirayil, Arun Pandiyan, Suresh Subramanian, Madhava B Mallia, Koramadai Karuppusamy Kamaleshwaran, Ajit Shinto
{"title":"Preparation of Rhenium-188-Lipiodol Using Freeze-Dried Kits for Transarterial Radioembolization: An Overview and Experience in a Hospital Radiopharmacy.","authors":"Edathurutykalarickal Ramakurup Radhakrishnan,&nbsp;Viju Chirayil,&nbsp;Arun Pandiyan,&nbsp;Suresh Subramanian,&nbsp;Madhava B Mallia,&nbsp;Koramadai Karuppusamy Kamaleshwaran,&nbsp;Ajit Shinto","doi":"10.1089/cbr.2021.0043","DOIUrl":"https://doi.org/10.1089/cbr.2021.0043","url":null,"abstract":"<p><p><b><i>Background:</i></b> Rhenium-188(<sup>188</sup>Re)-lipiodol is a clinically effective, economically viable radiopharmaceutical for Selective Internal Radiation Therapy of liver cancer. Present study evaluates the performance of three freeze-dried kits with respect to the radiochemistry, quality control, and overall \"ease of preparation\" aspects in a hospital radiopharmacy. <b><i>Materials and Methods:</i></b> Freeze-dried kits of acetylated 4-hexadecyl-4,7-diaza-1,10-decanedithiol (AHDD), super six sulfur (SSS), and diethyl dithiocarbamate (DEDC), obtained commercially or received as gift, were used for the preparation of <sup>188</sup>Re-lipiodol using freshly eluted <sup>188</sup>Re-sodium perrhenate from commercial Tungsten-188/<sup>188</sup>Re generator following recommended procedures. <b><i>Results:</i></b> The overall yield of <sup>188</sup>Re-lipiodol prepared using AHDD Kit, SSS Kit, and DEDC Kit was 74.82% ± 3.3%, 87.55% ± 4.8%, and 76.38% ± 4.6%, respectively. Observed radiochemical purity (RCP) of <sup>188</sup>Re-lipiodol prepared using these kits was 88.65% ± 2.8%, 92.92% ± 3.0%, and 91.38% ± 3.0%, respectively. Using a modified version of the DEDC Kits, overall yield of 87.17% ± 2.7% and RCP of 95.43% ± 2.3% could be achieved. <b><i>Conclusions:</i></b> While all three freeze-dried kits can be used for the preparation of <sup>188</sup>Re-lipiodol in >70% overall yield, the modified version of DEDC Kits has some advantages in terms of preparation time and volume of Rhenium-188 activity that can be added to the kit vial. The latter feature of the DEDC Kit is particularly useful for patient dose preparation with <sup>188</sup>Re activity of low radioactive concentration.</p>","PeriodicalId":518937,"journal":{"name":"Cancer biotherapy & radiopharmaceuticals","volume":" ","pages":"63-70"},"PeriodicalIF":3.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39073076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Negative Histopathological Prognostic Factors Affecting Morbidity in T1 Differentiated Thyroid Carcinoma. 影响T1分化甲状腺癌发病率的阴性组织病理学预后因素。
IF 3.4
Cancer biotherapy & radiopharmaceuticals Pub Date : 2022-02-01 Epub Date: 2021-09-15 DOI: 10.1089/cbr.2020.4679
Mine Araz, Elgin Özkan, Pınar Gunduz, Cigdem Soydal, N Özlem Küçük, K Metin Kır
{"title":"Negative Histopathological Prognostic Factors Affecting Morbidity in T1 Differentiated Thyroid Carcinoma.","authors":"Mine Araz,&nbsp;Elgin Özkan,&nbsp;Pınar Gunduz,&nbsp;Cigdem Soydal,&nbsp;N Özlem Küçük,&nbsp;K Metin Kır","doi":"10.1089/cbr.2020.4679","DOIUrl":"https://doi.org/10.1089/cbr.2020.4679","url":null,"abstract":"<p><p><b><i>Background:</i></b> The aim was to evaluate: (i) if multifocality is a negative prognostic factor; and (ii) the association of diameter of the largest tumor, total tumor diameter, and the ratio of the largest tumor diameter to total tumor diameter (DR) with histopathological and clinical outcome parameters in T1 differentiated thyroid carcinoma (DTC). <b><i>Materials and Methods:</i></b> In 1014 T1N0/1Mx patients, correlation between multifocality, contralateral lobe involvement, capsular-vascular invasion, diameter of the largest tumor, total tumor diameter, DR, and follow-up results were investigated. <b><i>Results:</i></b> Persistent/recurrent disease and necessity for additional radioiodine treatment (RAIT) were more frequent in cases with multifocality and contralateral lobe involvement (<i>p</i> = 0.035, <i>p</i> = 0.015, <i>p</i> = 0.021, and <i>p</i> = 0.04). Persistence/recurrence, reoperation in the neck, and additional RAIT were more frequent in patients with the size of the largest tumor focus >1 cm (<i>p</i> = 0.024, <i>p</i> < 0.001, and <i>p</i> = 0.002) and N1 status (<i>p</i> < 0.001, <i>p</i> < 0.001, and <i>p</i> < 0.001). Mean total tumor diameter was higher in patients with capsular invasion, contralateral lobe, and lymph node involvement (<i>p</i> = 0.001, <i>p</i> = 0.003, and <i>p</i> = 0.013). <b><i>Conclusion:</i></b> Multifocality, contralateral lobe involvement, diameter of the largest tumor >1 cm, and N1 status are related with increased risk of disease persistence, recurrence, reoperation, and additional RAIT. Sum of diameter of all tumor foci are associated with capsular invasion.</p>","PeriodicalId":518937,"journal":{"name":"Cancer biotherapy & radiopharmaceuticals","volume":" ","pages":"56-62"},"PeriodicalIF":3.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39418936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (177Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors. 血液学指标作为晚期神经内分泌肿瘤患者应用Lutetium 177 (177Lu)-DOTATATE治疗结果的预测指标
IF 3.4
Cancer biotherapy & radiopharmaceuticals Pub Date : 2022-02-01 Epub Date: 2021-06-29 DOI: 10.1089/cbr.2021.0053
Swayamjeet Satapathy, Anish Bhattacharya, Ashwani Sood, Rakesh Kapoor, Rajesh Gupta, Apurva Sood, Prashant Sharma, Divya Khosla, Bhagwant Rai Mittal
{"title":"Hematological Markers as Predictors of Treatment Outcomes with Lutetium 177 (<sup>177</sup>Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors.","authors":"Swayamjeet Satapathy,&nbsp;Anish Bhattacharya,&nbsp;Ashwani Sood,&nbsp;Rakesh Kapoor,&nbsp;Rajesh Gupta,&nbsp;Apurva Sood,&nbsp;Prashant Sharma,&nbsp;Divya Khosla,&nbsp;Bhagwant Rai Mittal","doi":"10.1089/cbr.2021.0053","DOIUrl":"https://doi.org/10.1089/cbr.2021.0053","url":null,"abstract":"Background: Chronic inflammation has been linked to the development and prognosis of neuroendocrine tumors (NETs). The current study intended to evaluate the role of peripheral hematological inflammatory markers, viz. the platelet-lymphocyte ratio (PLR), neutrophil-lymphocyte ratio, and monocyte-lymphocyte ratio, as predictors of treatment outcomes in patients with advanced NETs after Lu-177 DOTATATE therapy. Materials and Methods: Data of consecutive patients with advanced metastatic and/or inoperable NETs treated with Lu-177 DOTATATE from the year 2012 to 2019 at the authors' center were retrospectively analyzed. Results: Forty-two NET patients (median age: 49.5 years) received a median cumulative activity of 29.6 GBq of Lu-177 DOTATATE over 2-5 cycles at 8-12-week intervals. The median progression-free survival (PFS) of the study cohort was 30 months (95% confidence interval, CI: 18.2-41.9 months). A baseline PLR ≥173.1 was found to be a significant predictor of poor PFS with a univariate hazard ratio of 3.82 (95% CI: 1.21-12.03); however, the association was not significant on multivariate analysis. The median overall survival was not reached and none of the parameters were significantly associated with it. Conclusions: A higher baseline PLR was shown to be associated with a negative outcome on PFS after 177Lu-DOTATATE therapy and is a promising marker for future larger studies.","PeriodicalId":518937,"journal":{"name":"Cancer biotherapy & radiopharmaceuticals","volume":" ","pages":"23-29"},"PeriodicalIF":3.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39050655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Targeted α-Therapy. 有针对性的α治疗。
IF 3.4
Cancer biotherapy & radiopharmaceuticals Pub Date : 2020-08-01 Epub Date: 2020-06-05 DOI: 10.1089/cbr.2020.29008.mbr
Martin W Brechbiel
{"title":"Targeted α-Therapy.","authors":"Martin W Brechbiel","doi":"10.1089/cbr.2020.29008.mbr","DOIUrl":"https://doi.org/10.1089/cbr.2020.29008.mbr","url":null,"abstract":"","PeriodicalId":518937,"journal":{"name":"Cancer biotherapy & radiopharmaceuticals","volume":" ","pages":"397"},"PeriodicalIF":3.4,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.2020.29008.mbr","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38017742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Targeted Alpha Therapy and Nanocarrier Approach. 靶向α治疗和纳米载体方法。
IF 3.4
Cancer biotherapy & radiopharmaceuticals Pub Date : 2020-08-01 Epub Date: 2020-02-28 DOI: 10.1089/cbr.2019.3213
Mine Silindir-Gunay, Merve Karpuz, A Yekta Ozer
{"title":"Targeted Alpha Therapy and Nanocarrier Approach.","authors":"Mine Silindir-Gunay,&nbsp;Merve Karpuz,&nbsp;A Yekta Ozer","doi":"10.1089/cbr.2019.3213","DOIUrl":"https://doi.org/10.1089/cbr.2019.3213","url":null,"abstract":"<p><p>The rates of cancer incidence and mortality are increasing day by day. Although several conventional methods including surgery, chemotherapy, and radiotherapy (RT) exist for cancer treatment, they are insufficient in the eradication of all tumor tissues and have some side-effects such as narrow therapeutic index and serious side-effects to healthy tissues. Moreover, it may probably recur in time due to the survival and spreading of cancerous cells or any possible metastases. Targeted radionuclide therapy is a promising alternative. α particles are ideal for localized cell killing because of their high linear energy transfer and short ranges. However, upon emission of α particles, the daughter nuclides induce a recoil energy to lead decoupling from any chemical bond that may accumulate in normal tissues. Targeted α therapy can also be performed by targeted delivery systems apart from mAb, mAb fragments, peptides, and small molecules for selective tumor therapy. Targeted drug delivery systems have been developed to overcome the limitations of α therapy. Moreover, drug delivery systems are one of the most searched applications in cancer imaging and/or treatment due to their targeting ability to tumor or biocompatibility properties. The aim of this article is to summarize tumor therapy applications, targeted α RT approach, and to review the role of drug delivery systems in the delivery of α particles for cancer therapy and some instances of targeted α-emitting drug delivery systems from the literature.</p>","PeriodicalId":518937,"journal":{"name":"Cancer biotherapy & radiopharmaceuticals","volume":" ","pages":"446-458"},"PeriodicalIF":3.4,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.2019.3213","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37844043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Targeted Alpha Therapy: Current Clinical Applications. 靶向α疗法:目前的临床应用。
IF 3.4
Cancer biotherapy & radiopharmaceuticals Pub Date : 2020-08-01 Epub Date: 2020-06-16 DOI: 10.1089/cbr.2020.3576
Francisco D C Guerra Liberal, Joe M O'Sullivan, Stephen J McMahon, Kevin M Prise
{"title":"Targeted Alpha Therapy: Current Clinical Applications.","authors":"Francisco D C Guerra Liberal,&nbsp;Joe M O'Sullivan,&nbsp;Stephen J McMahon,&nbsp;Kevin M Prise","doi":"10.1089/cbr.2020.3576","DOIUrl":"https://doi.org/10.1089/cbr.2020.3576","url":null,"abstract":"<p><p>α-Emitting radionuclides have been approved for cancer treatment since 2013, with increasing degrees of success. Despite this clinical utility, little is known regarding the mechanisms of action of α particles in this setting, and accurate assessments of the dosimetry underpinning their effectiveness are lacking. However, targeted alpha therapy (TAT) is gaining more attention as new targets, synthetic chemistry approaches, and α particle emitters are identified, constructed, developed, and realized. From a radiobiological perspective, α particles are more effective at killing cells compared to low linear energy transfer radiation. Also, from these direct effects, it is now evident from preclinical and clinical data that α emitters are capable of both producing effects in nonirradiated bystander cells and stimulating the immune system, extending the biological effects of TAT beyond the range of α particles. The short range of α particles makes them a potent tool to irradiate single-cell lesions or treat solid tumors by minimizing unwanted irradiation of normal tissue surrounding the cancer cells, assuming a high specificity of the radiopharmaceutical and good stability of its chemical bonds. Clinical approval of <sup>223</sup>RaCl<sub>2</sub> in 2013 was a major milestone in the widespread application of TAT as a safe and effective strategy for cancer treatment. In addition, <sup>225</sup>Ac-prostate specific membrane antigen treatment benefit in metastatic castrate-resistant prostate cancer patients, refractory to standard therapies, is another game-changing piece in the short history of TAT clinical application. Clinical applications of TAT are growing with different radionuclides and combination therapies, and in different clinical settings. Despite the remarkable advances in TAT dosimetry and imaging, it has not yet been used to its full potential. Labeled <sup>227</sup>Th and <sup>225</sup>Ac appear to be promising candidates and could represent the next generation of agents able to extend patient survival in several clinical scenarios.</p>","PeriodicalId":518937,"journal":{"name":"Cancer biotherapy & radiopharmaceuticals","volume":" ","pages":"404-417"},"PeriodicalIF":3.4,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.2020.3576","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38061043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 46
The Relationship Between Total Lesion Activity on 18F Choline Positron Emission Tomography-Computed Tomography and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Bone Metastases Treated with 223Radium. 223镭治疗去势抵抗性前列腺癌骨转移患者18F胆碱正电子发射断层扫描-计算机断层扫描病灶总活动性与临床预后的关系
IF 3.4
Cancer biotherapy & radiopharmaceuticals Pub Date : 2020-08-01 Epub Date: 2020-02-28 DOI: 10.1089/cbr.2019.3188
Luca Filippi, Pietro Basile, Orazio Schillaci, Oreste Bagni
{"title":"The Relationship Between Total Lesion Activity on <sup>18</sup>F Choline Positron Emission Tomography-Computed Tomography and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Bone Metastases Treated with <sup>223</sup>Radium.","authors":"Luca Filippi,&nbsp;Pietro Basile,&nbsp;Orazio Schillaci,&nbsp;Oreste Bagni","doi":"10.1089/cbr.2019.3188","DOIUrl":"https://doi.org/10.1089/cbr.2019.3188","url":null,"abstract":"<p><p>The aim of the study was to assess the correlation between metabolic response measured through positron emission tomography-computed tomography (PET-CT) with <sup>18</sup>F choline (<sup>18</sup>F FCH) and overall survival (OS) in patients affected by bone lesions from metastatic castration-resistant prostate cancer treated with <sup>223</sup>Ra dichloride. Eleven subjects were subjected to PET-CT with <sup>18</sup>F FCH before and 1 month after <sup>223</sup>Ra treatment. Reduction in total lesion activity (ΔTLA) between pretreatment and post-treatment scan was determined and patients were divided into responders (ΔTLA >50%) and nonresponders (ΔTLA <50%). The OS of the entire cohort was 12.7 ± 3.8 months. Kaplan-Meier analysis showed that responders presented a significantly longer survival than nonresponders (16.5 ± 1.9 months vs. 10.5 ± 0.9 months, <i>p</i> < 0.05). Reduction in TLA after <sup>223</sup>Ra treatment seems to be correlated with a trend toward a longer survival.</p>","PeriodicalId":518937,"journal":{"name":"Cancer biotherapy & radiopharmaceuticals","volume":" ","pages":"398-403"},"PeriodicalIF":3.4,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/cbr.2019.3188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37686670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信